Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol: An ex vivo and in vivo study using an NC/Nga mouse model

Zahid Hussain, Haliza Katas, Mohd Cairul Iqbal Mohd Amin, Kumolosasi Msi Endang, Fhataheya Buang, Shariza Sahudin

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

In this study, hydroxytyrosol (HT; a potent antioxidant) was co-administered with hydrocortisone (HC) to mitigate the systemic adverse effects of the latter and to provide additional anti-inflammatory and antioxidant benefits in the treatment of atopic dermatitis (AD). The co-loaded nanoparticles (NPs) prepared had shown different particle sizes, zeta potentials, loading efficiencies, and morphology, when the pH of the chitosan solution was increased from 3.0 to 7.0. Ex vivo permeation data showed that the co-loaded NPs formulation significantly reduced the corresponding flux (17.04 μg/cm2/h) and permeation coefficient (3.4 × 10-3 cm/h) of HC across full-thickness NC/Nga mouse skin. In addition, the NPs formulation showed higher epidermal (1560 ± 31 μg/g of skin) and dermal (880 ± 28 μg/g of skin) accumulation of HC than did a commercial HC formulation. Moreover, an in vivo study using an NC/Nga mouse model revealed that compared to the other treatment groups, the group treated with the NPs formulation efficiently controlled transepidermal water loss (13 ± 2 g/m2/h), intensity of erythema (207 ± 12), and dermatitis index (mild). In conclusion, NPs co-loaded with HC/HT is proposed as a promising system for the percutaneous co-delivery of anti-inflammatory and antioxidative agents in the treatment of AD.

Original languageEnglish
Pages (from-to)109-119
Number of pages11
JournalInternational Journal of Pharmaceutics
Volume444
Issue number1-2
DOIs
Publication statusPublished - 28 Feb 2013

Fingerprint

Nanoparticles
Hydrocortisone
Skin
Atopic Dermatitis
Anti-Inflammatory Agents
Antioxidants
Chitosan
Dermatitis
Erythema
Particle Size
3,4-dihydroxyphenylethanol
Water

Keywords

  • Allergic contact dermatitis
  • Corticosteroid
  • Polymeric nanoparticles
  • Polyphenol
  • Topical co-delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{e872e91dc6fb4388901074f5e5b2fb4a,
title = "Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol: An ex vivo and in vivo study using an NC/Nga mouse model",
abstract = "In this study, hydroxytyrosol (HT; a potent antioxidant) was co-administered with hydrocortisone (HC) to mitigate the systemic adverse effects of the latter and to provide additional anti-inflammatory and antioxidant benefits in the treatment of atopic dermatitis (AD). The co-loaded nanoparticles (NPs) prepared had shown different particle sizes, zeta potentials, loading efficiencies, and morphology, when the pH of the chitosan solution was increased from 3.0 to 7.0. Ex vivo permeation data showed that the co-loaded NPs formulation significantly reduced the corresponding flux (17.04 μg/cm2/h) and permeation coefficient (3.4 × 10-3 cm/h) of HC across full-thickness NC/Nga mouse skin. In addition, the NPs formulation showed higher epidermal (1560 ± 31 μg/g of skin) and dermal (880 ± 28 μg/g of skin) accumulation of HC than did a commercial HC formulation. Moreover, an in vivo study using an NC/Nga mouse model revealed that compared to the other treatment groups, the group treated with the NPs formulation efficiently controlled transepidermal water loss (13 ± 2 g/m2/h), intensity of erythema (207 ± 12), and dermatitis index (mild). In conclusion, NPs co-loaded with HC/HT is proposed as a promising system for the percutaneous co-delivery of anti-inflammatory and antioxidative agents in the treatment of AD.",
keywords = "Allergic contact dermatitis, Corticosteroid, Polymeric nanoparticles, Polyphenol, Topical co-delivery",
author = "Zahid Hussain and Haliza Katas and {Mohd Amin}, {Mohd Cairul Iqbal} and Endang, {Kumolosasi Msi} and Fhataheya Buang and Shariza Sahudin",
year = "2013",
month = "2",
day = "28",
doi = "10.1016/j.ijpharm.2013.01.024",
language = "English",
volume = "444",
pages = "109--119",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol

T2 - An ex vivo and in vivo study using an NC/Nga mouse model

AU - Hussain, Zahid

AU - Katas, Haliza

AU - Mohd Amin, Mohd Cairul Iqbal

AU - Endang, Kumolosasi Msi

AU - Buang, Fhataheya

AU - Sahudin, Shariza

PY - 2013/2/28

Y1 - 2013/2/28

N2 - In this study, hydroxytyrosol (HT; a potent antioxidant) was co-administered with hydrocortisone (HC) to mitigate the systemic adverse effects of the latter and to provide additional anti-inflammatory and antioxidant benefits in the treatment of atopic dermatitis (AD). The co-loaded nanoparticles (NPs) prepared had shown different particle sizes, zeta potentials, loading efficiencies, and morphology, when the pH of the chitosan solution was increased from 3.0 to 7.0. Ex vivo permeation data showed that the co-loaded NPs formulation significantly reduced the corresponding flux (17.04 μg/cm2/h) and permeation coefficient (3.4 × 10-3 cm/h) of HC across full-thickness NC/Nga mouse skin. In addition, the NPs formulation showed higher epidermal (1560 ± 31 μg/g of skin) and dermal (880 ± 28 μg/g of skin) accumulation of HC than did a commercial HC formulation. Moreover, an in vivo study using an NC/Nga mouse model revealed that compared to the other treatment groups, the group treated with the NPs formulation efficiently controlled transepidermal water loss (13 ± 2 g/m2/h), intensity of erythema (207 ± 12), and dermatitis index (mild). In conclusion, NPs co-loaded with HC/HT is proposed as a promising system for the percutaneous co-delivery of anti-inflammatory and antioxidative agents in the treatment of AD.

AB - In this study, hydroxytyrosol (HT; a potent antioxidant) was co-administered with hydrocortisone (HC) to mitigate the systemic adverse effects of the latter and to provide additional anti-inflammatory and antioxidant benefits in the treatment of atopic dermatitis (AD). The co-loaded nanoparticles (NPs) prepared had shown different particle sizes, zeta potentials, loading efficiencies, and morphology, when the pH of the chitosan solution was increased from 3.0 to 7.0. Ex vivo permeation data showed that the co-loaded NPs formulation significantly reduced the corresponding flux (17.04 μg/cm2/h) and permeation coefficient (3.4 × 10-3 cm/h) of HC across full-thickness NC/Nga mouse skin. In addition, the NPs formulation showed higher epidermal (1560 ± 31 μg/g of skin) and dermal (880 ± 28 μg/g of skin) accumulation of HC than did a commercial HC formulation. Moreover, an in vivo study using an NC/Nga mouse model revealed that compared to the other treatment groups, the group treated with the NPs formulation efficiently controlled transepidermal water loss (13 ± 2 g/m2/h), intensity of erythema (207 ± 12), and dermatitis index (mild). In conclusion, NPs co-loaded with HC/HT is proposed as a promising system for the percutaneous co-delivery of anti-inflammatory and antioxidative agents in the treatment of AD.

KW - Allergic contact dermatitis

KW - Corticosteroid

KW - Polymeric nanoparticles

KW - Polyphenol

KW - Topical co-delivery

UR - http://www.scopus.com/inward/record.url?scp=84873702901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873702901&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2013.01.024

DO - 10.1016/j.ijpharm.2013.01.024

M3 - Article

C2 - 23337632

AN - SCOPUS:84873702901

VL - 444

SP - 109

EP - 119

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -